Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoukos, D. H.en
dc.contributor.authorLorenz, M.en
dc.contributor.authorEncke, A.en
dc.date.accessioned2015-11-24T19:17:19Z-
dc.date.available2015-11-24T19:17:19Z-
dc.identifier.issn0039-6060-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21764-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectEsophagectomyen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectGastrectomyen
dc.subjectHumansen
dc.subjectLymph Node Excision/*methodsen
dc.subjectLymphatic Metastasisen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectPancreatectomyen
dc.subjectProspective Studiesen
dc.subjectSplenectomyen
dc.subjectStomach Neoplasms/*mortality/pathology/*surgeryen
dc.subjectSurvival Analysisen
dc.subjectSurvival Rateen
dc.subjectTime Factorsen
dc.titleEvidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1067/msy.1998.88094-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9591011-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0039606098001494/1-s2.0-S0039606098001494-main.pdf?_tid=b36a541c1fa496709a9bdead93fa5a01&acdnat=1333704655_5cc3a56f5d7d174bcc66007486b963af-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1998-
heal.abstractBACKGROUND: The use of extended (D2) lymph node dissection in gastric cancer achieves better locoregional tumor control than limited (D1) lymphadenectomy, but its influence on survival is controversial. The value of D2 resection is unproven in randomized trials. However, a survival benefit in favor of D2 resection has been shown in reports from some specialized centers. This study was undertaken to assess whether D2 resection improves survival. We evaluated the efficacy of D2 resection on the basis of a new concept that eliminates the stage migration phenomenon. METHODS: D2 resection achieved with a standardized technique in this prospective study included dissection of the perigastric lymph nodes (stations 1 through 6, D1 resection), as well as those at the celiac axis (stations 7 through 11) and at hepatoduodenal ligament (station 12, N2 level). We evaluated survival data of patients with involved nodes at stations 7 through 12 (N2 disease) because these nodes are left behind in a D1 resection. RESULTS: D2 resection resulted in a resection of cure in 31 patients with N2 disease, a 25% (31 of 125) increase of the curative resection compared with a supposed D1 resection. The 5-year survival rate for N2 patients was 17%, which demonstrates the therapeutic benefit of the D2 resection. In patients with pN0 and pN1 disease, the 5-year survival rates were 71% and 53%, respectively. Overall hospital mortality and morbidity were 1.3% (2 of 146) and 33.4% (40 of 146), respectively. CONCLUSIONS: D2 resection can be performed safely and is of therapeutic value in patients with advanced lymph node metastases. Furthermore, the survival data suggest indirectly a possible beneficial effect for patients with node-negative disease (N0) or early node metastases (N1).en
heal.journalNameSurgeryen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Roukos-1998-Evidence of survival.pdf34.73 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons